Journal of Vaccine Research 2024, Vol.14, No.6, 316-323 http://medscipublisher.com/index.php/jvr 321 8 Concluding Remarks mRNA vaccines have revolutionized the vaccinology science by providing an effective, rapid and responsive approach to prevent disease. Specifically during the COVID-19 pandemic, the efficacy of mRNA vaccines has demonstrated its ability to generate an intense and lasting immune response with less side effect. Compared to traditional vaccine platforms, mRNA vaccines possess significant strengths, including the ability to rapidly produce and respond to combat re-emerging infectious disease. In addition, the synthetic character of mRNA vaccines makes them amenable to low-cost production and mass promotion, and therefore it is a promising asset in global health programs. Yet, there are certain technical concerns that need to be addressed in order to reach the full promise of mRNA vaccines. Some areas where additional research is needed include improving the stability and efficiency of delivery of mRNA molecules and enhancing the immunogenicity of vaccines. Optimization of lipid nanoparticle formulations and other delivery systems is critical to effective delivery in vivo and reducing the dependence on rigorous storage conditions. Furthermore, understanding of the quality attributes that impact translation effectiveness and immune response is also necessary for vaccine design and manufacturing process optimization. Continued investment in translational science and early-phase clinical trials will strengthen vaccine candidates and expand their use in other infectious diseases and cancers. mRNA vaccine technology has a powerful long-term impact on public health. With the progress of technology, it will serve as a powerful platform for pandemics and future emerging infectious disease. Flexibility and scalability of mRNA vaccines will also enable personalized vaccines development, and individualized vaccination based on specific genetic characteristics will revolutionize preventive medicine. In addition to this, lowered costs of production and higher production levels will boost global vaccination efforts, especially in low-income countries, thereby closing health gaps and enhancing overall public health. Continuous research and development in this field has the promise of a vision for health in the future, and mRNA vaccines will be in the lead when it comes to fighting a number of diseases and ultimately benefit human society as a whole. Acknowledgments Thanks to all the collaborators and data providers participating in this study, and their support is an important guarantee for the smooth progress of this study. Conflict of Interest Disclosure The authors affirm that this research was conducted without any commercial or financial relationships that could be construed as a potential conflict of interest. References Am A., 2023, Recent advances in mRNA vaccine development, Open Access Journal of Microbiology and Biotechnology, 10. https://doi.org/10.23880/oajmb-16000275 Chavda V., Soni S., Vora L., Soni S., Khadela A., and Ajabiya J., 2022, mRNA-based vaccines and therapeutics for COVID-19 and future pandemics, Vaccines, 10(12): 2150. https://doi.org/10.3390/vaccines10122150 Chen J., Chen J., and Xu Q., 2022, Current developments and challenges of mRNA vaccines, Annual Review of Biomedical Engineering, 24. https://doi.org/10.1146/annurev-bioeng-110220-031722 Chu L., McPhee R., Huang W., Bennett H., Pajon R., Nestorova B., and Leav B., 2021, A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine, Vaccine, 39: 2791-2799. https://doi.org/10.1016/j.vaccine.2021.02.007 Crommelin D., Anchordoquy T., Volkin D., Jiskoot W., and Mastrobattista E., 2020, Addressing the cold reality of mRNA vaccine stability, Journal of Pharmaceutical Sciences, 110(3): 997-1001. https://doi.org/10.1016/j.xphs.2020.12.006 Fayez N., Nassar M., Alshehri A., Alnefaie M., Almughem F., Alshehri B., Alawad A., and Tawfik E., 2023, Recent advancement in mRNA vaccine development and applications, Pharmaceutics, 15(7): 1972. https://doi.org/10.3390/pharmaceutics15071972 Feng P., Gu D.N., and Wang Y.F., 2024, Analysis of improvements to the chickenpox vaccine and the development of new vaccines, Journal of Vaccine Research, 14(1): 1-9. https://doi.org/10.5376/jvr.2024.14.0001
RkJQdWJsaXNoZXIy MjQ4ODYzNQ==